Completed PHASE1 INTERVENTIONAL 2-arm NCT02079506

Pharmacokinetic Drug Interaction Between Candesartan and Rosuvastatin

An Open-label, Multiple-dosing, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Candesartan 32 mg and Rosuvastatin 20 mg in Healthy Male Volunteers

Sponsor: Alvogen Korea

Conditions Healthy

Interventions Candesartan Rosuvastatin

Updated 5 times since 2017 Last updated: Mar 4, 2014 Started: Feb 28, 2014 Primary completion: Feb 28, 2014 Completion: Feb 28, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02079506, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Alvogen Korea, it has been updated 5 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2017 — Jan 2021 [monthly]

Completed PHASE1

First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alvogen Korea

Data source: Alvogen Korea

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jung-gu, South Korea